ARDS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ARDS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Aridis Pharmaceuticals's gross profit for the three months ended in Sep. 2023 was $0.00 Mil. Aridis Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Sep. 2023 was $19.65 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Aridis Pharmaceuticals's gross profit for the three months ended in Sep. 2023 was $0.00 Mil. Aridis Pharmaceuticals's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, Aridis Pharmaceuticals's Gross Margin % for the quarter that ended in Sep. 2023 was N/A%.
Aridis Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Sep. 2023 => No sustainable competitive advantage
The historical data trend for Aridis Pharmaceuticals's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aridis Pharmaceuticals Annual Data | ||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||
Gross Profit | Get a 7-Day Free Trial | 2.76 | - | - | - | - |
Aridis Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Gross Profit | Get a 7-Day Free Trial | - | - | - | 19.65 | - |
For the Biotechnology subindustry, Aridis Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Aridis Pharmaceuticals's Gross Profit distribution charts can be found below:
* The bar in red indicates where Aridis Pharmaceuticals's Gross Profit falls into.
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Aridis Pharmaceuticals's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as
Gross Profit (A: Dec. 2022 ) | = | Revenue | - | Cost of Goods Sold |
= | 0 | - | 0 | |
= | 0.00 |
Aridis Pharmaceuticals's Gross Profit for the quarter that ended in Sep. 2023 is calculated as
Gross Profit (Q: Sep. 2023 ) | = | Revenue | - | Cost of Goods Sold |
= | 0 | - | 0 | |
= | 0.00 |
Gross Profit for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.65 Mil.
Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)
Aridis Pharmaceuticals's Gross Margin % for the quarter that ended in Sep. 2023 is calculated as
Gross Margin % (Q: Sep. 2023 ) | = | Gross Profit (Q: Sep. 2023 ) | / | Revenue (Q: Sep. 2023 ) |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | 0.00 | / | 0 | |
= | N/A % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Aridis Pharmaceuticals (OTCPK:ARDS) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Aridis Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Sep. 2023 => No sustainable competitive advantage
Thank you for viewing the detailed overview of Aridis Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Vu Truong | director, 10 percent owner, officer: CEO, CSO, Director | 5941 OPTICAL CT., SAN JOSE CA 95138 |
Eric Patzer | director, 10 percent owner | 5941 OPTICAL CT., SAN JOSE CA 95138 |
Fibrosis Foundation Cystic | 10 percent owner | 4550 MONTGOMERY STREET, SUITE 1100N, BETHESDA MD 20814 |
Hasan Jafri | officer: Chief Medical Officer | 5941 OPTICAL COURT, SAN JOSE CA 95138 |
John F Hamilton | director | 1360 O'BRIEN DR, MENLO PARK CA 94025 |
Michael Adrian Nazak | officer: Chief Financial Officer | 5941 OPTICAL COURT, SAN JOSE CA 95138 |
Susan Richards Windham-bannister | director | 78 BLANCHARD ROAD, BURLINGTON MA 01803 |
Isaac Blech | director | C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116 |
Fred Kurland | officer: Chief Financial Officer | C/O GENITOPE CORP, 525 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
Wolfgang Dummer | officer: Chief Medical Officer | 5491 OPTICAL CT., SAN JOSE CA 95138 |
Robert R Ruffolo | director | |
Shawn Lu | director | C/O CANTEX PHARMACEUTICALS, INC., 1792 BELL TOWER LANE, WESTON FL 33326 |
Robert K. Coughlin | director | 5941 OPTICAL CT., SAN JOSE CA 95138 |
Craig S Gibbs | director | C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025 |
From GuruFocus
By GuruFocus Research • 02-12-2024
By Value_Insider Value_Insider • 11-22-2022
By sperokesalga sperokesalga • 05-31-2023
By sperokesalga sperokesalga • 04-26-2023
By PRNewswire PRNewswire • 08-10-2022
By Marketwired • 06-24-2024
By sperokesalga sperokesalga • 03-31-2023
By sperokesalga sperokesalga • 06-08-2023
By GlobeNewswire • 06-24-2024
By Stock market mentor Stock market mentor • 01-25-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.